Please assess the completion status of the following clinical trial:

Trial Title: Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Essential Thrombocythemia per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms.~* Requires treatment in order to lower platelet count based on patient age over 60 or history of thrombosis.~* Have failed at least one standard therapy~* Must have discontinued ET therapy at least 1 week (4 weeks for interferon) prior to study drug initiation.~Exclusion Criteria:~* Has undergone major surgery ≤4 weeks prior to starting study drug or has not recovered from side effects of such surgery.~* Unresolved treatment related toxicities from prior therapies (unless resolved to ≤ Grade 1).~* Uncontrolled active infection.~* Current use of prohibited medications~* Known HIV infection or active Hepatitis B or Hepatitis C virus infection~* Other hematologic/biochemistry requirements, as per protocol~* Use of investigational agent within last 14 days~* Pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bomedemstat (Type: EXPERIMENTAL): Bomedemstat administered daily for 169 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).